REFERENCES
- Morris STW, Mcmurray JJV, Spiers A, Jardine AG. Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int. 2001;60:1077–1082.
- Flecka C, Schweitzera F, Kargea E, Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clinica Chimica Acta. 2003;336:1–12.
- Morris ST, McMurray J, Rodger R, Impaired endothelium-dependent vasodilatation in uraemia. Nephrol Dial Transplant. 2000;15:1194–1200.
- Hand MF, Haynes WG, Webb DJ. Hemodialysis and L-arginine, but not D-arginine, correct renal-failure associated endothelial dysfunction. Kidney Int. 1998;53:1068–1077.
- Kari JA, Donald AE, Vallance DT, Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int. 1997;52:468–472.
- Ravani P, Tripepi G, Malberti F, Asymmetrical dimethyl- arginine predicts progression to dialysis and death in patients with chronic kidney disease: A competing risks modeling approach. J Am Soc Nephrol. 2005;16:2449–2455.
- Lajer M, Tarnow L, Jorsal A, Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2008;31:747–752.
- Zoccali C, Bode B, Mallamaci F, Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet. 2001;358:2113–2117.
- Lu TM, Ding YA, Lin SJ, Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J. 2003;24:1912–1919.
- Schnabel R, Blankenberg S, Lubos E, Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: Results from the AtheroGene study. Circ Res. 2005;97:53–59.
- Valkonen VP, Päivä H, Salonen JT, Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001;358:2127–2128.
- Schulzc F, Lenzen H, Hanefeld C, Asymmetric dimethyl- arginine is an independent risk factor for coronary heart disease: Results from the multicenter Coronary Artery Risk Determination investigating the influnce of ADMA Concentration (CARDIAC) study. Am Heart J. 2006;152(3):493.
- Chaytan C, Gupta B, Meindel N, Fractional directi dialysis quantification: A new approach for prescription and monitoring hemodialysis therapy. Kidney Int. 1996;50(6):1845–1849.
- Russell CD, Bischoff PG, Kontzen FN, Measurement of glomerular filtration rate: Single injection plasma clearance method without urine collection. J Nucl Med. 1985;26(11):1243–1247.
- Anderstam B, Katzatski K, Bergström J. Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol. 1997;8:1437–1442.
- Kielstein JT, Böger RH, Bode-Böger SM, Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol. 1999;10:594–600.
- Kielstein JT, Böger RH, Bode-Böger SM, Low dialysance of asymmetric dimethylarginine (ADMA) – in vivo and in vitro evidence of significant protein binding. Clin. Nephrol. 2004;62(4):295–300.
- Panichi V, Mantuano E, Paoletti S, Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. J Nephrol. 2008;21:38–44.
- Wahbi N, Dalton RN, Turner C, Dimethylarginines in chronic renal failure. J Clin Pathol. 2001;54:470–473.
- Böger RH, Zoccali C. ADMA: A novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atherosclerosis Suppl. 2003;4:23–28.
- Teerlink T. ADMA metabolism and clearance. Vasc Med. 2005;10(Suppl. 1):S73–S81.
- Carello KA, Whitesall SE, Lloyd MC, Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats. Am J Physiol Heart Circ Physiol. 2006;290:H209–H216.
- Ebinç FA, Erten Y, Ebinç H, The relationship among asymmetric dimethylarginine (ADMA) levels, residual renal function, and left ventricular hypertrophy in continuous ambulatory peritoneal dialysis patients. Renal Failure. 2008;30:401–406.